NX Development Corp.
NX Development Corp. is a US-based life sciences company that commercializes Gleolan®, an FDA-approved optical imaging agent enabling real-time fluorescence-guided brain tumor surgery, sold directly to neurosurgery departments across 400+ US hospitals.
- Company typePrivate
- Founded2010
- HeadquartersLouisville, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What NX Development Corp. does
NX Development Corp. (NXDC) is a US-based life sciences company that commercializes Gleolan® (aminolevulinic acid hydrochloride / 5-ALA), an FDA-approved optical imaging agent indicated as an adjunct for visualization of malignant tissue during brain tumor resection in patients with glioma (suspected WHO Grades III or IV). Gleolan is administered orally at 20mg/kg 2-4 hours pre-surgery and acts as a prodrug metabolized intracellularly to Protoporphyrin IX, which accumulates selectively in tumor cells and emits red-violet fluorescence under blue light excitation (375-440nm), enabling real-time intraoperative visualization that complements conventional white-light microscopy. The company received original FDA approval in 2017 and is actively pursuing label expansion via the MEN-301 Phase 3 study for meningioma (supplemental NDA submitted April 2026) and the OVA-302 Phase 3 study for epithelial ovarian cancer (FDA Orphan Drug Designation granted March 2024).
The business is structured as a direct enterprise field sales operation targeting neurosurgery departments at US hospitals and surgical centers, with adoption across 400+ centers and 1,100+ surgeons in the United States and cumulative use in 120,000+ patients across 50+ countries. In April 2025, NXDC regained full US sales and marketing rights from Medexus Pharmaceuticals and relaunched Gleolan under the NXDC brand at the AANS conference in Boston; the company reported record-breaking unit sales in the one-year anniversary update through June 2026. Revenue derives from institutional, quote-based procurement of a single product with no publicly disclosed pricing. NXDC is a wholly-owned subsidiary of photonamic GmbH & Co. KG (Pinneberg, Germany), itself part of the SBI Holdings, Inc. (Tokyo) corporate group, providing integrated development and international commercialization infrastructure.
NX Development Corp. firmographics
Firmographics- Name
- NX Development Corp.
- Legal name
- NX Development Corp.
- Website
- https://nxdevcorp.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- NX Development Corp. is a US-based life sciences company that commercializes Gleolan®, an FDA-approved optical imaging agent enabling real-time fluorescence-guided brain tumor surgery, sold directly to neurosurgery departments across 400+ US hospitals.
- Ownership category
- akta.pro rank
NX Development Corp. industry classification
Industry- Product category
- Intraoperative Optical Imaging Agents
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Neuro-oncology (HLAKAIAL)
- akta.pro secondary industry
- Neuro-Oncology (HLAKAFAH)
Keywords
Where NX Development Corp. is headquartered
LocationHeadquarters
- HQ city
- Louisville
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
NX Development Corp. business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Revenue model
- Gleolan Product Sales: NX Development Corp generates revenue through the sale of Gleolan (aminolevulinic acid HCl), an FDA-approved optical imaging agent used during brain tumor resection surgery. The company regained full commercial control of Gleolan in the US market in April 2025, reporting record-breaking unit sales in June 2026. Revenue is derived from direct sales to hospitals and surgical centers performing glioma and other cancer surgeries.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
NX Development Corp. product offering
Product offeringCore offering
NX Development Corp. develops and commercializes Gleolan® (aminolevulinic acid hydrochloride), an FDA-approved orally administered optical imaging agent used as an adjunct during brain tumor resection surgery. The prodrug is metabolized to Protoporphyrin IX, which selectively accumulates in malignant cells and fluoresces under blue light excitation, enabling neurosurgeons to visualize tumor tissue in real time during high-grade glioma surgery. The company also pursues expanded indications through Phase 3 clinical studies in meningioma and ovarian cancer.
Product overview
NX Development Corp. offers a single flagship product—Gleolan®, an FDA-approved optical imaging agent used as an adjunct during brain cancer surgery. The drug is an orally-administered prodrug (aminolevulinic acid hydrochloride) that, when metabolized, causes tumor cells to fluoresce under blue light, enabling neurosurgeons to visualize and remove malignant tissue with precision in real-time. Originally approved in 2017 for high-grade glioma (WHO Grades III or IV), the company is actively pursuing expanded indications through clinical trials including meningioma (MEN-301 study) and ovarian cancer (OVA-302 study).
Differentiator
Problem solved
Functional benefit
Products and services
- Gleolan® (aminolevulinic acid hydrochloride) FDA-approved oral optical imaging agent (ALA HCl / 5-ALA) administered at 20mg/kg body weight 2-4 hours prior to brain tumor resection. Metabolized to Protoporphyrin IX, which selectively accumulates in tumor cells and emits red-violet fluorescence under blue light (375-440nm), enabling real-time visualization of malignant tissue for neurosurgeons operating on high-grade glioma.
Quantifiable outcome
- Over 120,000 patients have benefited from Gleolan use across over 50 countries
- +2 more outcomes
Companies that use NX Development Corp.
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
NX Development Corp. technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
NX Development Corp. partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered minor and core.
- Medexus Pharmaceuticals (Former)minorMedexus Pharmaceuticals previously held sales and marketing rights for Gleolan in the US market from 2022-2025. These rights returned to NXDC in April 2025. NXDC notes unresolved financial obligations remain due from Medexus that they are pursuing resolution for.
- Photonamic GmbH & Co. KGcoreIn 2018, NX Development Corp became a subsidiary of Photonamic GmbH & Co. KG, a global leader in developing fluorescence-based diagnostic and therapeutic technologies. This partnership strengthened NXDC's market position and enabled expansion of Gleolan's reach. Photonamic is wholly owned by SBI ALApharma (Hong Kong), a subsidiary of SBI Holdings Inc. (Tokyo, Japan). Dr. Ulrich Kosciessa serves as both Chairman of NXDC's Board and CEO of Photonamic.
Scale indicators5 records
Recent moves7 records
Expansion highlights6 records
NX Development Corp. competitors and assessment
Company assessmentDirect peers
- Photonamic GmbH & Co. KG: Parent company of NXDC and original developer of 5-ALA/ALA HCl technology. Operates the Gleolan franchise outside the US; directly comparable because it commercializes the same active ingredient in different geographies.
Emerging players
- Blaze Bioscience: Clinical-stage developer of tumor-paint (fluorescent peptide) imaging agents for fluorescence-guided cancer surgery. Comparable as a focused fluorescence-guided surgery imaging company targeting the same surgical oncology end users.
- Lumicell: Developer of an intraoperative fluorescence imaging system (LUM Imaging System) used to detect residual cancer during surgery. Comparable as a real-time intraoperative cancer visualization company with FDA pathway experience.
- Delcath Systems: Developer of an intraoperative/percutaneous hepatic delivery system with PHP for liver metastases. Comparable as a small specialty pharma/dev company commercializing an image-guided or procedure-adjacent oncology therapy through specialty centers.
- OnLume: Developer of fluorescence-guided surgery imaging hardware and software for veterinary and human surgical applications. Comparable as a smaller fluorescence-guided surgery imaging peer focused on intraoperative visualization.
Others
- Medexus Pharmaceuticals: Former US commercial partner for Gleolan (2022–2025). Relevant because Medexus operated the same product in the same channel and serves as a directly comparable specialty pharma commercial model for NXDC's relaunch.
Broad incumbents
- Novocure: Public oncology specialty company commercializing Tumor Treating Fields (Optune) for glioblastoma and other solid tumors. Comparable as a focused brain-tumor oncology company selling a unique adjunct therapy into the same neurosurgery/neuro-oncology customer base.
- Stryker (Surgical Imaging): Large medical device incumbent offering SPY fluorescence imaging platforms integrated into surgical suites. Comparable as a broader fluorescence-guided surgery imaging ecosystem player whose installed base and capital equipment shape Gleolan's addressable market.
- Leica Microsystems (Danaher): Major manufacturer of surgical microscopes with blue-light fluorescence modules used in neurosurgery. Comparable as the dominant capital equipment provider whose microscope fleet enables Gleolan's blue-light workflow.
- Carl Zeiss Meditec: Manufacturer of surgical microscopes (e.g., OPMI Pentero) with integrated fluorescence modes used in glioma resection. Comparable as a key surgical microscope vendor that defines the technical environment for Gleolan's adoption.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
NX Development Corp. social profiles
Digital presenceNX Development Corp. financial estimates
Financial estimateRevenue estimate
Valuation estimate
NX Development Corp. leadership team
Management profileNumber of profiles
Profiles2 records
NX Development Corp. funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NX Development Corp. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NX Development Corp.
What does NX Development Corp. do?
NX Development Corp. develops and commercializes Gleolan® (aminolevulinic acid hydrochloride), an FDA-approved orally administered optical imaging agent used as an adjunct during brain tumor resection surgery. The prodrug is metabolized to Protoporphyrin IX, which selectively accumulates in malignant cells and fluoresces under blue light excitation, enabling neurosurgeons to visualize tumor tissue in real time during high-grade glioma surgery. The company also pursues expanded indications through Phase 3 clinical studies in meningioma and ovarian cancer.
Is NX Development Corp. a public or private company?
NX Development Corp. is a private company. It is classified as corporate owned and is currently operating.
When was NX Development Corp. founded?
NX Development Corp. was founded in 2010. It employs 11 to 50 people.
Where is NX Development Corp. based?
NX Development Corp. is headquartered in Louisville, United States, in the North America region.
How does NX Development Corp. make money?
One revenue line is on record: gleolan Product Sales.
Who are NX Development Corp.'s main competitors?
Photonamic GmbH & Co. KG is listed as a direct peer. Emerging players are Blaze Bioscience, Lumicell, Delcath Systems and OnLume. Medexus Pharmaceuticals is listed as an others. Broad incumbents are Novocure, Stryker (Surgical Imaging), Leica Microsystems (Danaher) and Carl Zeiss Meditec.
Does NX Development Corp. have an API?
No public API is recorded for NX Development Corp..
What industry is NX Development Corp. in?
NX Development Corp.'s product category is Intraoperative Optical Imaging Agents. Its primary akta.pro industry code is HLAKAIAL, Neuro-oncology, with a secondary code of HLAKAFAH, Neuro-Oncology. Its NAICS code is 3254 and its SIC code is 2834.